Recently, Synaura Biotech (Shanghai) Co., Ltd. (‘Synaura Biotech’) has successfully secured nearly 100 million yuan in Pre-A round financing. This funding round was led by CICC Qide Fund, under the renowned investment institution CICC Capital, with participation from Moutai Fund. The capital raised will be allocated towards new product development, laboratory construction, industrialisation implementation, and commercialisation advancement, injecting fresh momentumSynaura Biotech's innovative development within the HMO sector.
Established in February 2022, Synaura Biotech stands as China's pioneering domestic HMO innovator, spearheading future nutritional trends with its proprietary HMO products. Its HMO offerings set new benchmarks in health nutrition through exceptional properties including high purity, low impurity levels, and odourlessness. Leveraging cutting-edge R&D capabilities and precision fermentation techniques, Synaura Biotech delivers solutions that meet both client innovation requirements and consumer demands for premium nutritional quality.
Dr Huang Xu, Managing Director of CICC Capital, remarked that HMOs have been a key focus for numerous dairy enterprises in recent years. Following formal approval in October 2023, they will spearhead a new wave of advancement within the infant formula and dairy sectors. As China's first approved enterprise, Synaura Biotech is poised to seize opportunities in the global nutritional supplements market and soar to new heights, bolstered by shareholder resources and driven by its dedicated management team.
Maotai Fund serves as the market-oriented equity investment platform under China Kweichow Moutai (Group) Co., Ltd. (‘Maotai Group’). Focusing on cutting-edge developments and applications in biotechnology, Maotai Fund has recognised Synaura Biotech's growth potential within the synthetic biology sector.
Existing shareholder Beihai Mengniu Venture Capital has made a follow-on investment in this round. As a wholly-owned incubator platform under Mengniu Group and a key component of its strategic investment arm, Beihai Mengniu Venture Capital participated in Synaura Biotech's founding through investment and incubation. This additional investment underscores Mengniu's confidence and commitment to its strategic positioning in the synthetic biology sector.
Moving forward, with the combined strengths of all shareholders, Synaura Biotech will accelerate the development of its R&D innovation capabilities. The company will prioritise the development of HMOs and new pipelines, further enhance its local HMO expertise and influence, continuously cultivate new productive forces, and contribute to the high-quality development of the dairy industry.
About CICC Capital
CICC Capital serves as the private equity fund management platform of China International Capital Corporation Limited (‘CICC’), overseeing the firm's domestic and international private investment fund operations. It has evolvedone of China's leading private investment management institutions. Currently, the funds under its management encompass RMB corporate equity funds, fund-of-funds, real estate funds, infrastructure funds, and USD corporate equity funds.
